Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma

Abstract The maximum tolerated dose of SAR245409 (voxtalisib), a pan-class I phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor, was determined in a phase 1 dose-escalation study in advanced solid tumors. We report safety, pharmacokinetics (PK), pharmacodynamics and preliminary efficacy of SAR245409 capsules 50 mg twice daily in an expansion cohort of 16 patients with relapsed/refractory lymphoma. The most common treatment-related adverse events (AEs) were nausea (31.3%) and diarrhea (25.0%). The most common grade 3/4 treatment-related AE was increased alanine aminotransferase (12.5%). PK results were consistent with solid tumors, confirming a relatively short steady-state half-life (mean 4.61 h). Among 12 evaluable patients, one complete response and two partial responses were achieved in patients with and without PI3K/mTOR pathway alterations. In a patient with mantle cell lymphoma achieving PR, SAR245409 was associated with significant inhibition of PI3K/mTOR and extracellular signal-related kinase (ERK) pathways. Preliminary efficacy warrants further evaluation of SAR245409 in lymphoma.

[1]  Yoonjin Cho,et al.  Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. , 2014, Blood.

[2]  J. Byrd,et al.  A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). , 2014, Blood.

[3]  K. Yamaguchi,et al.  Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway , 2014, Molecular Cancer Therapeutics.

[4]  G. Salles,et al.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.

[5]  Weiliang Shi,et al.  Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[6]  S. Chandarlapaty,et al.  Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. , 2014, Cancer discovery.

[7]  P. Zinzani,et al.  Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma. , 2013, Clinical advances in hematology & oncology : H&O.

[8]  M. Kersten,et al.  SAR245409 Monotherapy in relapsed/refractory follicular lymphoma: preliminary results from the phase II ARD12130 study , 2013 .

[9]  Manel Juan,et al.  Landscape of somatic mutations and clonal evolution in mantle cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[10]  B. Dörken,et al.  Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down‐regulation of Mcl‐1 in mantle cell lymphoma , 2013, International journal of cancer.

[11]  G. Lenz,et al.  PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[12]  Xin Wang,et al.  Blockade of PI3K/AKT pathway enhances sensitivity of Raji cells to chemotherapy through down-regulation of HSP70 , 2013, Cancer Cell International.

[13]  I. Flinn,et al.  Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory lymphoma. , 2013 .

[14]  M. Prados,et al.  Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study. , 2013 .

[15]  Guang Li,et al.  Inhibition of the PI3K/AKT-NF-κB pathway with curcumin enhanced radiation-induced apoptosis in human Burkitt's lymphoma. , 2013, Journal of pharmacological sciences.

[16]  M. Calaminici,et al.  P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. , 2013, Blood.

[17]  L. Staudt,et al.  Targeting pathological B cell receptor signalling in lymphoid malignancies , 2013, Nature Reviews Drug Discovery.

[18]  A. Younes,et al.  Targeting oncogenic and epigenetic survival pathways in lymphoma , 2013, Leukemia & lymphoma.

[19]  Dereje D. Jima,et al.  PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas , 2013, Clinical Cancer Research.

[20]  N. Nagy,et al.  Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study , 2013, BMC Cancer.

[21]  L. C. Chen,et al.  Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  A. Lazar,et al.  Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors , 2012, Molecular Cancer Therapeutics.

[23]  M. Ghielmini,et al.  A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma , 2012, Haematologica.

[24]  Razelle Kurzrock,et al.  A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.

[25]  Suzanne F. Jones,et al.  The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors. , 2012 .

[26]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Pan,et al.  Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder , 2011, Histopathology.

[28]  J. Ware,et al.  A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Mitchel S. Berger,et al.  Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. , 2011, Neuro-oncology.

[30]  Stephen L. Abrams,et al.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health , 2011, Oncotarget.

[31]  T. Habermann,et al.  A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma , 2010, Leukemia.

[32]  R. Ulrich,et al.  Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma , 2010 .

[33]  Scott E. Smith,et al.  Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Tabernero,et al.  Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs , 2010, Oncotarget.

[35]  H. Nilsson‐Ehle,et al.  High immunohistochemical expression of p‐AKT predicts inferior survival in patients with diffuse large B‐cell lymphoma treated with immunochemotherapy , 2010, British journal of haematology.

[36]  M. Lim,et al.  The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma , 2010, Leukemia.

[37]  A. Scorilas,et al.  Phosphatidylinositol 3′-Kinase Catalytic Subunit α Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma , 2009, Clinical Cancer Research.

[38]  B. Coiffier,et al.  Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  E. Sausville,et al.  Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy , 2009, Clinical Cancer Research.

[40]  F. Al-Dayel,et al.  PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma , 2007, Leukemia.

[41]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.